<!DOCTYPE html>
<html lang="en">
    <head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1">
        <title>30</title>

        <link href="bootstrap.min.css" rel="stylesheet">
        <link href="custom_arrow.css" rel="stylesheet" type="text/css"/>
        <link href="treatments.css" rel="stylesheet" type="text/css"/>
        <link href="recreated_tables.css" rel="stylesheet" type="text/css"/>
           <style>
        .sep {
            border-bottom:1px solid lightgray;
        }
        .sep td {
            padding-bottom:5px;
            padding-top:5px;
        }
        br {
            display: block;
            margin-top: 5px 0;
        }
    </style>
    </head>
    <body>
            <br />
            <div class="container">
                <ol class="breadcrumb small">
                
                        <li class="active">Herpes - Genital</li><li class="active">Recurrent Episode</li>
                </ol>
              </div><!-- end of breadcrumbs -->
            
        <div class="container"><h3>Suppressive Therapy for Recurrent Genital Herpes</h3>
<p>Suppressive therapy reduces the frequency of genital herpes recurrences by 70%–80% in patients who have frequent recurrences <sup id="fnref:345"><a class="footnote-ref" href="#fn:345" rel="footnote">1</a></sup>  <sup id="fnref:346"><a class="footnote-ref" href="#fn:346" rel="footnote">2</a></sup>  <sup id="fnref:347"><a class="footnote-ref" href="#fn:347" rel="footnote">3</a></sup>  <sup id="fnref:348"><a class="footnote-ref" href="#fn:348" rel="footnote">4</a></sup>; many persons receiving such therapy report having experienced no symptomatic outbreaks. Treatment also is effective in patients with less frequent recurrences. Safety and efficacy have been documented among patients receiving daily therapy with acyclovir for as long as 6 years and with valacyclovir or famciclovir for 1 year <sup id="fnref:350"><a class="footnote-ref" href="#fn:350" rel="footnote">5</a></sup>  <sup id="fnref:351"><a class="footnote-ref" href="#fn:351" rel="footnote">6</a></sup>. Quality of life is improved in many patients with frequent recurrences who receive suppressive therapy rather than episodic treatment <sup id="fnref:352"><a class="footnote-ref" href="#fn:352" rel="footnote">7</a></sup>.</p>
<p>The frequency of genital herpes recurrences diminishes over time in many persons, potentially resulting in psychological adjustment to the disease. Therefore, periodically during suppressive treatment (e.g., once a year), providers should discuss the need to continue therapy. However, neither treatment discontinuation nor laboratory monitoring in a healthy person is necessary.</p>
<p>Treatment with valacyclovir 500 mg daily decreases the rate of HSV-2 transmission in discordant, heterosexual couples in which the source partner has a history of genital HSV-2 infection <sup id="fnref:349"><a class="footnote-ref" href="#fn:349" rel="footnote">8</a></sup>. Such couples should be encouraged to consider suppressive antiviral therapy as part of a strategy to prevent transmission, in addition to consistent condom use and avoidance of sexual activity during recurrences. Suppressive antiviral therapy also is likely to reduce transmission when used by persons who have multiple partners (including MSM) and by those who are HSV-2 seropositive without a history of genital herpes.</p>
<p>Acyclovir, famciclovir, and valacyclovir appear equally effective for episodic treatment of genital herpes <sup id="fnref:342"><a class="footnote-ref" href="#fn:342" rel="footnote">9</a></sup>  <sup id="fnref:343"><a class="footnote-ref" href="#fn:343" rel="footnote">10</a></sup>  <sup id="fnref:344"><a class="footnote-ref" href="#fn:344" rel="footnote">11</a></sup>  <sup id="fnref:345"><a class="footnote-ref" href="#fn:345" rel="footnote">1</a></sup>  <sup id="fnref:346"><a class="footnote-ref" href="#fn:346" rel="footnote">2</a></sup>, but famciclovir appears somewhat less effective for suppression of viral shedding <sup id="fnref:353"><a class="footnote-ref" href="#fn:353" rel="footnote">12</a></sup>. Ease of administration and cost also are important considerations for prolonged treatment.</p>
<h3>Episodic Therapy for Recurrent Genital Herpes</h3>
<p>Effective episodic treatment of recurrent herpes requires initiation of therapy within 1 day of lesion onset or during the prodrome that precedes some outbreaks. The patient should be provided with a supply of drug or a prescription for the medication with instructions to initiate treatment immediately when symptoms begin.</p>
<div class="footnote">
<hr />
<ol>
<li id="fn:345">
<p>Diaz-Mitoma F, Sibbald RG, Shafran SD, et al. Collaborative Famciclovir Genital Herpes Research Group. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. JAMA 1998;280:887–92.&#160;<a class="footnote-backref" href="#fnref:345" rev="footnote" title="Jump back to footnote 1 in the text">&#8617;</a></p>
</li>
<li id="fn:346">
<p>Mertz GJ, Loveless MO, Levin MJ, et al. Collaborative Famciclovir Genital Herpes Research Group. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women:  a multicenter, double-blind, placebo-controlled trial. Arch Intern Med 1997;157:343–9.&#160;<a class="footnote-backref" href="#fnref:346" rev="footnote" title="Jump back to footnote 2 in the text">&#8617;</a></p>
</li>
<li id="fn:347">
<p>Reitano M, Tyring S, Lang W, et al. International Valaciclovir HSV Study Group. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis 1998;178:603–10.&#160;<a class="footnote-backref" href="#fnref:347" rev="footnote" title="Jump back to footnote 3 in the text">&#8617;</a></p>
</li>
<li id="fn:348">
<p>Romanowski B, Marina RB, Roberts JN, et al. Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. Sex Transm Dis 2003;30:226–31.&#160;<a class="footnote-backref" href="#fnref:348" rev="footnote" title="Jump back to footnote 4 in the text">&#8617;</a></p>
</li>
<li id="fn:350">
<p>Goldberg LH, Kaufman R, Kurtz TO, et al. Acyclovir Study Group. Long-term suppression of recurrent genital herpes with acyclovir: a 5-year benchmark. Arch Dermatol 1993;129:582–7.&#160;<a class="footnote-backref" href="#fnref:350" rev="footnote" title="Jump back to footnote 5 in the text">&#8617;</a></p>
</li>
<li id="fn:351">
<p>Fife KH, Crumpacker CS, Mertz GJ, et al. Acyclovir Study Group. Recurrence and resistance patterns of herpes simplex virus following cessation of  ≥6 years of chronic suppression with acyclovir. J Infect Dis 1994;169:1338–41.&#160;<a class="footnote-backref" href="#fnref:351" rev="footnote" title="Jump back to footnote 6 in the text">&#8617;</a></p>
</li>
<li id="fn:352">
<p>Bartlett BL, Tyring SK, Fife K, et al. Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial. J Clin Virol 2008;43:190–5.&#160;<a class="footnote-backref" href="#fnref:352" rev="footnote" title="Jump back to footnote 7 in the text">&#8617;</a></p>
</li>
<li id="fn:349">
<p>Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11–20.&#160;<a class="footnote-backref" href="#fnref:349" rev="footnote" title="Jump back to footnote 8 in the text">&#8617;</a></p>
</li>
<li id="fn:342">
<p>Chosidow O, Drouault Y, Leconte-Veyriac F, et al. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. Br J Dermatol 2001;144:818–24.&#160;<a class="footnote-backref" href="#fnref:342" rev="footnote" title="Jump back to footnote 9 in the text">&#8617;</a></p>
</li>
<li id="fn:343">
<p>Bodsworth NJ, Crooks RJ, Borelli S, et al. International Valaciclovir HSV Study Group. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. Genitourin Med 1997;73:110–6.&#160;<a class="footnote-backref" href="#fnref:343" rev="footnote" title="Jump back to footnote 10 in the text">&#8617;</a></p>
</li>
<li id="fn:344">
<p>Fife KH, Barbarash RA, Rudolph T, et al. The Valaciclovir International Herpes Simplex Virus Study Group. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection:  results of an international, multicenter, double-blind, randomized clinical trial. Sex Transm Dis 1997;24:481–6.&#160;<a class="footnote-backref" href="#fnref:344" rev="footnote" title="Jump back to footnote 11 in the text">&#8617;</a></p>
</li>
<li id="fn:353">
<p>Wald A, Selke S, Warren T, et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis 2006;33:529–33.&#160;<a class="footnote-backref" href="#fnref:353" rev="footnote" title="Jump back to footnote 12 in the text">&#8617;</a></p>
</li>
</ol>
</div>
        </div>
            </div>
        </div>
    </body>
</html>
        